Telbivudine Plus Adefovir Versus Lamivudine Plus Adefovir for Lamivudine-Resistant Chronic Hepatitis B: TeSLA Randomized Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Tae Hyung | - |
dc.contributor.author | Kim, Minkoo | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Suh, Sang Jun | - |
dc.contributor.author | Jung, Young Kul | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Um, Soon Ho | - |
dc.contributor.author | Il Lee, Jung | - |
dc.contributor.author | Lee, Sae Hwan | - |
dc.contributor.author | Kim, Sang Gyun | - |
dc.contributor.author | Kim, In Hee | - |
dc.contributor.author | Kim, Hyoung Su | - |
dc.contributor.author | Cho, Eun Young | - |
dc.contributor.author | Kim, Tae Yeob | - |
dc.contributor.author | Hwang, Seong Gyu | - |
dc.date.accessioned | 2022-11-04T06:42:09Z | - |
dc.date.available | 2022-11-04T06:42:09Z | - |
dc.date.created | 2022-11-04 | - |
dc.date.issued | 2021-11 | - |
dc.identifier.issn | 1735-143X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/144623 | - |
dc.description.abstract | Background: In countries with unavailable tenofovir, a combination of lamivudine (LMV) and adefovir (ADV) is recommended for the treatment of LMV-resistant chronic hepatitis B (CHB). Considering that telbivudine (L-dT) was demonstrated to be superior to LMV in previous studies, L-dT and ADV combination therapy is expected to show better antiviral efficacy than the combination of LMV and ADV in patients with LMV-resistant CHB. Methods: This was a prospective randomized multicenter study. The primary endpoint was Hepatitis B Virus (HBV) DNA reduction after 52 weeks of treatment. The secondary endpoints were HBV DNA undetectability, hepatitis B e antigen seroconversion, the incidence of virological and biochemical breakthroughs, and safety during the study period. Results: A total of 43 LMV-resistant CHB patients were enrolled. Twenty-one were treated with LMV + ADV and 22 with L-dT + ADV. After 52 weeks of antiviral treatment, the HBV DNA reduction showed no significant intergroup difference (-4.54 +/- 1.23 log IU/mL in the LMV + ADV group, -4.24 +/- 1.46 log IU/mL in the L-dT + ADV group, P = 0.475). There were no significant intergroup differences in HBV DNA undetectability rates, mean HBV DNA level, or hepatitis B e antigen seroconversion rate at 13, 26, 39, and 52 weeks of treatment. In terms of safety, the mean creatine phosphokinase level was significantly higher in the L-dT + ADV group. Conclusions: In the treatment of LMV-resistant CHB, the combination of L-dT and ADV did not show any clinical benefit compared to the combination of LMV and ADV. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | BRIEFLAND | - |
dc.subject | E-ANTIGEN SEROCONVERSION | - |
dc.subject | VIRUS | - |
dc.subject | DIPIVOXIL | - |
dc.subject | THERAPY | - |
dc.subject | INFECTION | - |
dc.title | Telbivudine Plus Adefovir Versus Lamivudine Plus Adefovir for Lamivudine-Resistant Chronic Hepatitis B: TeSLA Randomized Trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yim, Hyung Joon | - |
dc.contributor.affiliatedAuthor | Jung, Young Kul | - |
dc.identifier.doi | 10.5812/hepatmon.121627 | - |
dc.identifier.scopusid | 2-s2.0-85123557213 | - |
dc.identifier.wosid | 000789782900002 | - |
dc.identifier.bibliographicCitation | HEPATITIS MONTHLY, v.21, no.11 | - |
dc.relation.isPartOf | HEPATITIS MONTHLY | - |
dc.citation.title | HEPATITIS MONTHLY | - |
dc.citation.volume | 21 | - |
dc.citation.number | 11 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | E-ANTIGEN SEROCONVERSION | - |
dc.subject.keywordPlus | VIRUS | - |
dc.subject.keywordPlus | DIPIVOXIL | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordAuthor | Adefovir | - |
dc.subject.keywordAuthor | Hepatitis B | - |
dc.subject.keywordAuthor | Lamivudine Resistance | - |
dc.subject.keywordAuthor | Rescue Therapy | - |
dc.subject.keywordAuthor | Telbivudine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.